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Abstract: O b j e c t i v e: Th e aim of this study was to assess the prevalence of multimorbidity and co-ex-
isted diseases in hospitalized patients with heart failure (HF) in relation to age and gender.
M e t h o d s: Th e nationwide cross-sectional survey had been conducted in Poland (April-November 2013), 
in 260 randomly selected hospital wards. A trained nurse contacted with one physician, drawn from the list 
of all doctors working in the selected hospital’s wards, who completed the study questionnaires regarding to 
clinical characteristics of the last fi ve HF patients, who were discharged from an internal or cardiology ward.
R e s u l t s: Mean age ± SD of the patients was 72.1 ± 10.1 years, 50% were female but the women were 
signifi cantly older than men. Criterion of multimorbidity met almost 100% of the HF patients. Th ere were 
no signifi cant diff erences in the number of co-existed cardiovascular (CV) and non-CV diseases accord-
ing to gender, but diff erent clinical profi le of HF men and women was observed. Women more frequently 
had thyroid disease, peripheral artery disease and cognitive impairment, whereas men was characterized 
by higher prevalence of cardiac, pulmonary and hepatic diseases. Th e co-morbidity signifi cantly increased 
with age, notably due to increasing prevalence of non-CV diseases. Diabetes, chronic kidney disease, 
hypercholesterolemia and anemia were the most common non-CV diseases. Among HF patients, 83% 
suff ered from three or more co-morbidities.
C o n c l u s i o n s: T h e  study confi rms, that multimorbidity is a considerable problem in patients with 
HF. Besides age, multimorbidity pattern is strongly dependent on gender. Th e multidisciplinary approach 
is warranted in particular in elderly subjects who suff er from HF.
Key words: heart failure, multimorbidity, co-morbidity, hospital settings, cross-sectional survey.
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Introduction
Heart failure (HF) is a  clinical syndrome characterized by high morbidity and 
mortality rates and it is an increasingly important public health problem — it is 
estimated that there is about 23 million patients worldwide with HF [1]. Prevalence 
of HF has increased with age up to 17.4% among subjects 85 years of age or older [2]. 
It has been estimated that in the Polish population 700-800 thousand people are 
currently suff ering from HF [3, 4], and more than one in fi ve people will experience 
HF at some point in their lives [5]. On the basis of data from the National Health 
Fund  (NHF) in Poland in 2016 nearly 160 thousand hospitalizations related to HF 
occurred, of which about 10% ended in death [6]. In Europe, the observational Heart 
Failure Pilot Survey (ESC-HF Pilot) showed 12-month hospitalization rate of 44% 
among hospitalized patients with HF. Moreover, 12 month all-cause mortality rate 
was 17% and most deaths were due to cardiovascular (CV) causes [7].
Multimorbidity is defi ned as the co-occurrence of at least two chronic diseases 
or medical problems [8], and its related to disability, worsening of quality of life 
and higher health care costs  [9]. In the studies which have been undertaken so far, 
the incidence of multimorbidity was shown to be disparate, due to the different 
populations included in the study, various settings and defi nition [10]. According to 
the American data, more than one quarter of adults have multimorbidity [11]. HF 
mostly is accompanied by co-existing illnesses which further aggravate the quality 
of life and prognosis, mainly because of the higher risk of adverse drugs reactions, 
great possibility of drugs interactions, confl icting medical advice, and unnecessary 
hospitalizations. Th e majority (74%) of outpatients with chronic HF in Europe have 
at least one co-morbidity [12]. Among the most common co-existing chronic diseases 
were chronic kidney disease (CKD), anemia, diabetes [12], chronic obstructive 
pulmonary disease (COPD), depression and lower respiratory diseases  [13], and 
all of them were independently associated with increased risk of mortality and 
hospitalization. Moreover, it was shown that risk of hospital admission strongly raised 
with the number of coexisting chronic conditions [13]. Van Deursen et al. showed 
the association between the prevalence of co-morbidities and age, higher heart rate as 
well as ischaemic aetiology of HF and more severe signs of HF expressed by the New 
York Heart Association (NYHA) functional classifi cation [12].
Th e aim of the study was to assess multimorbidity and co-existed chronic diseases 
in HF patients admitted to the hospital, independently of the cause of hospitalization. 
Th ese issues were considered through the prism of the potential age and gender 
diff erences.
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Materials and methods
Study design
Th e cross-sectional, nationwide, retrospective survey on HF management in hospital 
settings had been conducted in 2013 in Poland. Th e study methods have been 
published elsewhere [14]. In brief, the survey was carried out in 260 hospital wards 
randomly selected from the Registry of Entities Carrying out Medical Activities 
(Rejestr Podmiotów Wykonujących Działalność Leczniczą) — dated on April 2013. 
Th e method of stratifi ed sampling was used for selection of the hospitals. Th e fi rst 
stratum was one of the 16 voivodships, the second included regional, provincial, urban 
and university hospitals having internal wards, internal wards with cardiac beds and 
cardiology units. Th e trained nurses contacted physicians invited to the study and ask 
them to complete the study questionnaires concerning clinical characteristics of the 
patients and their management during the hospital stay. From the surveyed hospital 
ward one physician was asked to collect the data of the last fi ve HF patients recently 
discharged from the hospital ward.
Patients’ inclusion and exclusion criteria
Th e patients included to the survey had to have HF listed under the ‘heading diagnosis’ 
in the patient discharge card, however HF did not have to be the main cause of the 
surveyed hospitalization. Th e patient had to be discharged from the hospital ward in 
a  stable health condition. A currently treated for oncologic condition was the only 
criterion excluding from the study.
Data collected
Data on patients’ characteristics (gender, age), chronic diseases, past medical history 
on myocardial infarction (MI), stroke or transient ischemic attack (TIA), and major 
clinical conditions (hypercholesterolemia, cognitive impairment) were gathered up. 
Based on these data, the number of CV and non-CV diseases or clinical conditions 
was calculated, as well as the total number of concomitant diseases in HF patients 
was established. In addition, the selected results of the clinical assessment of the HF 
patients’ status, such as a left  ventricular ejection fraction (EF) extracted from the last 
echocardiography performed during the surveyed hospitalization and patients’ NYHA 
class at their admission to the hospital ward were obtained. 
Multimorbidity was assessed in the patients according to the most common 
defi nition as two or more chronic diseases or major medical conditions [8].
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Ethical issues
Data were collected and processed maintaining confi dentiality and anonymity of the 
surveyed patients and the physicians participating in the study. Th e study was approved 
by the Bioethics Committee of the Jagiellonian University (no. KBET/71/B/2011).
Statistical analysis
Continuous variables were summarized and presented as mean ± standard deviation 
(SD). Ordinal variables or variables not normally distributed were presented as median 
and quartile range (upper-lower quartile). Data on frequency were given as numbers and 
percentages. Th e comparative analyses were based on the Student’s t-test or the Wilcoxon 
test, and the Chi-square test for qualitative data. Th e Cochrane-Armitage trend test or 
univariate analysis of variance were used to assess age-related changes, and  Spearman 
correlation used to assess the relationship between number of co-morbidities and 
parameters of HF severity. Two-sided tests were used and the P-value was set at <0.05. 
Data were managed and analyzed using SAS v. 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Characteristic of the patients
Mean age (± SD) of the HF patients admitted to hospital was 72.1 ± 10.1 years, 26.3% 
of the patients were aged 80 years or above. In the study sample, proportions of women 
and men were equal, but women were signifi cantly older (Table 1). At least two thirds 
of the patients had ischemic etiology of HF and majority of them were admitted to 
hospital due to the exacerbation of HF. Most of the studied population was classifi ed 
on admission at NYHA III–IV class — more frequently women than men (Table  1). 
In the elderly and in women the higher left  ventricular ejection fraction (LVEF) was 
observed. Th e elderly HF patients were more frequently hospitalized in internal wards, 
whereas the younger ones and men stayed more oft en in cardiology units.
Multimorbidity and comorbidity — gender and age diff erences
In fact, almost 100% of the surveyed HF patients were burdened multimorbidity, 
independently of gender (Table 2) and age (Table 3).
In men, cardiologic diseases were observed more frequently than in women 
(Table 2). Signifi cantly more men suff ered in the past from MI, as well as from valvular 
heart diseases, dilated cardiomyopathy and paroxysmal atrial fi brillation  (AF). In 
women, the vascular diseases such peripheral artery disease (PAD) and hypertension 
were observed more frequently. 
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Table 1. Characteristic of the 1281 heart failure patients according to their age and gender.
Gender Age
Women
n = 640
Men 
n = 641 p-value
≤59 yrs
n = 144
60–79 yrs
n = 800
≥80 yrs
n = 337
p-value
ǂ for 
trend 
Age, years 75.2 ± 9.4 70.0 ± 9.8 <0.001 54.7 ± 4.3 70.4 ± 5.6 83.9 ± 3.6 <0.001 
Female, n (%) – – 42 (29.2) 357 (44.6) 241 (71.5) <0.001ǂ
HF as the main cause of 
hospitalization 489 (76.1) 468 (72.9) 0.195 105 (72.9) 604 (75.5) 244 (72.4) 0.502
ǂ
HF cause≠
ischemic (CHD/MI) 390 (60.8) 392 (61.0) 0.937 79 (54.9) 477 (59.6) 223 (66.2) 0.010 ǂ
hypertension 136 (21.2) 156 (24.3) 0.188 33 (22.9) 187 (23.4) 72 (21.4) 0.576 ǂ
arrhythmia 245 (38.3) 161 (25.0) <0.001 25 (17.4) 265 (33.1) 116 (34.7) 0.002ǂ
valvular diseases 107 (16.7) 115 (17.9) 0.564 13 (9.0) 145 (18.1) 63 (18.7) 0.038ǂ 
diabetes 119 (18.5) 95 (14.8) 0.070 18 (12.5) 132 (16.5) 64 (19.0) 0.083ǂ
infl ammatory  40 (6.2) 22 (3.4) 0.019 8 (5.6) 36 (4.5) 18 (5.3) 0.885ǂ
toxic   9 (1.4) 29 (4.5) 0.001 14 (9.7) 23 (2.9) 1 (0.3) <0.001ǂ
NYHA class at admission
I–II 143 (22.3) 174 (27.4)
0.017
37 (25.9) 212 (26.7) 66 (19.7)
0.092III 364 (56.8) 311 (48.9) 77 (53.8) 415 (52.2) 181 (54.0)
IV 134 (20.9) 151 (23.7) 29 (20.3) 168 (21.1) 88 (26.3)
LVEF
number of available data 
(%) 528 474 113 650 236
LVEF, % 45 [35–52] 35 [29–48] <0.001  30 [25–46] 42 [30–50] 49 [38–55] <0.001ǂ
Type of hospital ward
internal 167 (58.2) 120 (41.8)
<0.001ǂ
23 (8.0) 140 (48.8) 124 (43.2)
<0.001internal with cardiology beds 310 (53.6) 268 (46.4) 52 (9.0) 383 (66.3) 143 (24.7)
cardiology 163 (39.2) 253 (60.8) 69 (16.6) 277 (66.6) 70 (16.8)
# based on the physician’s knowledge or available data  # p-value for trend (the Cochrane-Armitage trend test).
Abbreviations: HF, heart failure; CHD, coronary heart disease; MI, myocardial infarction; NYHA, New York 
Heart Association; LVEF, left  ventricular ejection fraction.
Data are presented as means ± standard deviation or median [upper-lower quartile].
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Table 2. Multimorbidity and co-morbidity in HF patients admitted to the hospital according to the gender. 
Women
n = 640
Men
n = 641 p-value
Multimorbidity 
Two or more diseases, n (%) 639 (99.8) 633 (98.8) 0.038
CV co-existing diseases, n (%) 
Hypertension 527 (82.1) 494 (76.8) 0.062
Coronary heart disease 449 (70.2) 445 (69.4) 0.836
Myocardial infarction 185 (28.8) 243 (37.8) 0.003
Stroke or TIA 92 (14.3) 73 (11.4) 0.292
Valvular heart disease 162 (25.2) 197 (30.6) 0.031
Dilated cardiomyopathy 88 (13.7) 159 (24.7) <0.001
Atrial fi brillation 
persisted 245 (38.2) 234 (36.7) 0.502
paroxysmal 117 (18.2) 131 (20.4) 0.046
Peripheral artery disease 189 (29.4) 127 (19.8) <0.001
Abdominal aortic aneurysm ≥ 6 cm 1 (0.9) 13 (2.0) 0.403
Number of co-existing CV diseases 2 [2–3] 2 [2–3] 0.241
Non-CV co-morbidities, n (%)
Diabetes 251 (39.1) 228 (35.5) 0.177
Hypercholesterolemia 191 (29.8) 242 (37.6) 0.003
COPD or asthma 99 (15.4) 128 (19.9) 0.041
Chronic kidney disease 229 (35.7) 203 (31.6) 0.120
Th yroid disease 127 (19.8) 88 (13.7) 0.009
Hepatitis or cirrhosis 16 (2.5) 30 (4.7) 0.036
Peptic ulcer disease 46 (7.2) 49 (7.6) 0.294
Connective tissue disease 6 (0.9) 8 (1.2) 0.851
Neoplastic disease 26 (4.1) 23 (3.6) 0.645
Tumor with metastasis 0 (0.0) 4 (0.6) 0.085
Anemia 151 (23.5) 141 (21.9) 0.496
Cognitive impairment 57 (8.9) 12 (1.9) <0.001
Number of non-CV diseases 2 [1–3] 2 [1–3] 0.421
Total number of co-morbidities 4 [3–5] 4 [3–5] 0.624
≥3 co-morbidities, n (%) 538 (84.1) 524 (81.8) 0.299
Abbreviations: TIA, transient ischemic attack; CV, cardiovascular; COPD, chronic obstructive pulmonary disease.
Data are presented as median [upper-lower quartile] or number (percentage).
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Th ere were no signifi cant diff erences in the number of non-CV co-morbidities 
between men and women (Table 2), however the diff erent clinical profi les of HF 
men and women have been found. In the surveyed HF men, pulmonary and liver 
diseases had been diagnosed more oft en, whereas in HF women — thyroid diseases. 
Th ere were no signifi cant gender-related diff erences in our HF patients with regard 
to prevalence of diabetes, CKD or anemia, however these co-morbidities were more 
common in HF women than in men. Distribution of the number of the co-morbidities 
in HF men and women presents the Fig. 1 (Panel A).
A
B
Fig. 1. Distribution of total co-morbidities according to the gender (Panel A) and age-category (Panel B).
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Table 3. Multimorbidity and co-morbidity in HF patients admitted to the hospital in relation to the 
age-category. 
≤59 yrs
n = 144
60–79 yrs
n = 800
80+ yrs
n = 337 P-value 
Multimorbidity 
Two or more diseases, n (%) 144 (100.0) 791 (98.9) 337 (100.0) 0.445ǂ
CV co-existing diseases, n (%) 
Hypertension 103 (71.5) 660 (82.5) 256 (76.0) 0.001
Coronary heart disease 98 (68.1) 543 (68.1) 250 (74.6) 0.080
Myocardial infarction 46 (31.9) 281 (35.1) 99 (29.5) 0.057
Stroke or TIA 5 (3.5) 96 (12.1) 64 (19.0) <0.001ǂ
Valvular heart disease 34 (23.6) 219 (27.4) 105 (31.2) 0.074 ǂ
Dilated cardiomyopathy 55 (38.5) 161 (20.8) 28 (9.6) <0.001ǂ
Atrial fi brillation 
persisted 24 (16.7) 303 (38.0) 150 (44.6) <0.001ǂ
paroxysmal 29 (20.1) 160 (20.2) 57 (17.0) 0.292
Peripheral artery disease 19 (13.2) 188 (23.5) 109 (32.3) <0.001ǂ
Abdominal aortic aneurysm ≥6 cm 1 (0.7) 16 (2.0) 3 (0.9) 0.109
Number of co-existing CV diseases 2 [2–3] 2 [2–3] 2 [2–3] 0.424
Non-CV co-morbidities, n (%)
Diabetes 37 (25.7) 313 (39.1) 129 (38.3) 0.054 ǂ
Hypercholesterolemia 53 (36.8) 278 (34.8) 99 (29.4) <0.001
COPD or asthma 25 (17.4) 146 (18.3) 56 (16.6) 0.523
Chronic kidney disease 27 (18.8) 258 (32.2) 147 (43.6) <0.001ǂ
Th yroid disease 16 (11.1) 130 (16.3) 66 (19.6) 0.016 ǂ
Hepatitis or cirrhosis 12 (8.3) 32 (4.0) 2 (0.6) <0.001ǂ
Peptic ulcer disease 11 (7.6) 53 (6.6) 31 (9.2) 0.587
Connective tissue disease 0 (0.0) 10 (1.2) 4 (1.2) 0.543
Neoplastic disease 2 (1.4) 29 (3.6) 18 (5.3) 0.036ǂ
Tumor with metastasis 3 (2.1) 1 (0.1) 0 (0.0) 0.032ǂ
Anemia 21 (14.6) 150 (18.8) 120 (35.6) <0.001ǂ
Dementia 0 (0.0) 15 (1.9) 54 (16.0) <0.001ǂ
Number of non-CV diseases 1 [1–2] 2 [1–2] 2 [1–3] <0.001
Total number of co-morbidities 4 [2–5] 4 [3–5] 4 [3–6] <0.001ǂ
≥3 co-morbidities, n (%) 106 (73.6) 668 (83.5) 288 (85.5) 0.006 ǂ
Abbreviations: TIA, transient ischemic attack; CV, cardiovascular; COPD, chronic obstructive pulmonary disease.
Data are presented as median [upper-lower quartile] or number (percentage).
ǂ p-value for trend (the Cochrane-Armitage trend test).
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With age, no signifi cant increase of the number of CV diseases was observed 
(Table 3). However, MI and dilated cardiomyopathy had been recognized less 
frequently in the octogenarians than in the younger patients. Whereas, they suff ered 
from stroke and transient ischemic attack (TIA), paroxysmal AF and PAD more 
frequently. Moreover, in the elderly HF patients non-CV co-morbidities had been 
observed more frequently (Table 3) — the most common were CKD, anemia, diabetes, 
thyroid diseases and cognitive impairments. In general, the percentage of the HF 
patients with co-occurence of additional three or more diseases was 83% (Table 3), 
and the number of co-morbidities signifi cantly increased with age — Fig. 1 (panel B).
HF characteristics and co-morbidity
In the patients with severe HF (NYHA class IV), signifi cantly more co-morbidities 
were observed than in those with NYHA class I–III, respectively: 4 [3–6] vs. 4 [3–5], 
p = 0.009. No signifi cant diff erences between the patients staged with NYHA I–IV 
classes were observed in relation to the number of CV and non-CV diseases.
A significant inverse correlation was observed between the total number of 
co-morbidities and LVEF (Fig. 2). The further analysis showed the significant 
relationship only with regards to the number of CV co-morbidities and LVEF 
(r = −0.172, p <0.001); the higher number of non-CV diseases was not associated 
with signifi cant reduction of LVEF (r = −0.009, p = 0.767).
Legend: Spearman correlation r = –0.116, p <0.001
Fig. 2. Association between left  ventricular ejection fraction (LVEF) and the total number of 
co-morbidities (NCH).
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Discussion
Summary of the results
In our study, multimorbidity criterion met almost all the HF patients. We found that 
those aged 60 years and older were hospitalized in internal medicine wards, whereas 
the younger ones in cardiology units more oft en. Th ere was no statistical signifi cance 
in the number of co-existed chronic diseases and clinical conditions according to the 
gender, however a  diff erent clinical profi les in HF men and women were observed. 
Th e total number of co-existed chronic diseases in HF patients signifi cantly increased 
with age, mostly due to the increasing prevalence of non-CV comorbidities. Th e 
total number of the co-existed diseases was signifi cantly related to the severity of 
HF symptoms expressed by the NYHA class and reduction of the LVEF, however 
the worsening of LVEF was not observed with increase number of the non-CV 
comorbidities.
Multimorbidity and co-morbidity
Th e systematic review of 41 studies has shown older age, female gender, and the lower 
level of education as the main risk factors for multimorbidity [9]. In our analysis, 
we showed that almost all examined HF patients were burdened with multimorbidity. 
Th erefore, the further scope was placed on the analysis of HF as an index disease, 
with respect to the co-existing co-morbidities and its determinants.
Cardiovascular diseases, such as hypertension, coronary heart disease (CHD), 
arrhythmias were the most common concomitant diseases in our study, as well as in 
the previously published data [4, 15], as they remain etiologic factors for HF. With 
regard to the etiology of HF, our results were comparable to the results obtained in 
other studies which showed that the predominant cause of HF was ischemic heart 
disease [3, 16, 17].
In some cases, the cause of HF might be difficult to establish or may be 
multifactorial, not necessary only related to the CV diseases. In our study, among 
non-CV diseases, diabetes, CKD, hypercholesterolemia as well as anemia aff ected 
patients hospitalized with HF most frequently, and has been in line with some of 
the previous reports [4, 12]. However, some recently published results have shown 
a  diff erent data on the most frequent non-CV diseases accompanying HF, which 
may results from many reasons (study populations, regional conditions). Th e Italian 
study indicated that the most common co-morbidity in the HF patients admitted 
to hospitals in Italy was COPD [18]. The data from the European Heart Failure 
Pilot Survey showed that the patients from the Eastern Europe had less CKD and 
anemia, and the highest prevalence of diabetes, compared with the other European 
regions [12]. 
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Our study highlighted the different clinical profiles of HF men and women, 
which was also observed in the other studies [19]. Additionally, the age- and gender- 
related diff erences has been found in the HF patients hospitalized at the internal and 
cardiology wards. 
Moreover,  in  the  presented  study,  similarly  as  in  the  previously  published 
ones [12, 20], it has been shown that the number of concomitant diseases, especially 
the non-CV diseases, increased with advanced age of HF patient. Th is may suggest 
that in HF patients also non-CV co-morbidities might be responsible for the increased 
risk of re-hospitalization of older patients compared to the younger population of 
patients with HF.
Consequences of the co-existed diseases in HF
Edelmann’s et al. study, which aimed to evaluate the relative impact of multiple 
co-morbidities on physical function using SF-36 physical functioning score 
(SF-36 PF score) and NYHA classifi cation in HF patients, showed that almost all CV 
and non-CV co-morbidities, with exception of hypertension and obesity, were more 
frequent in HF patients with reduced EF (rEF). Most of the co-existed diseases had 
a negative eff ect on patients’ general condition by increasing NYHA class and reducing 
SF-36 PF score, both in patients with rEF and with preserved EF (pEF). Obesity, 
CHD, PAD have been found to be especially unfavourable for patients with  pEF. 
Interestingly, they found a  much stronger impact of co-morbidities on NYHA class 
and physical impairment in patients with pEF than with rEF [21].
Moreover, in a  study of Chamberlain’s et al., the patients with pEF had higher 
prevalence of chronic conditions with exception of osteoporosis, diabetes and 
cancer [22]. Th e observation seems particularly important given the fact that elderly 
patients and women are more likely to develop HF with pEF [23, 24]. In our study, 
we also found that older patients had higher LVEF which might suggest the potential 
relationship between the higher prevalence of non-CV diseases and the more 
frequently observed normal LVEF in this group. 
In the study of Braunstein et al., it was demonstrated that in the elderly HF 
population (>65 years old) risk of hospitalization was strongly increased with the 
higher number of chronic non-CV diseases [13]. Moreover, the study indicated 
that COPD, CKD, diabetes, depression and other lower respiratory diseases were 
associated with notably higher risk of hospitalizations and mortality. Similarly, in the 
study of Muzzarelli et al. it was indicated that most of readmissions were caused by 
the non-CV co-morbidities [25] such as anemia, renal failure, and depression. In Van 
Deursen’s study it was found that the higher risk of mortality and hospitalizations in 
HF patients was independently associated with diagnosis of diabetes, CKD and anemia, 
as well as it was related to the number of co-morbidities  [12]. Th e  TEMISTOCLE 
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study has shown that HF patients with co-existing chronic diseases such as: COPD, 
CKD, anemia and/or thyroid disease, had longer stay in hospital, higher in-hospital 
mortality and also less often underwent non-invasive and invasive procedures 
compared to patients without these co-existed diseases [18].
Th e results of the previously published studies suggest that the chronic conditions, 
with other than HF pathophysiological pathways, might have a  negative impact on 
outcomes of the patients with HF. Th is might be determined through the infl uence 
of polypharmacy, drug — drug, drug — diseases and disease — disease interactions, 
as well as diffi  culties in obtaining the optimal management and care coordination. 
A more comprehensive approach to diagnosis and treatment of patients with HF 
may improve the prognosis and the quality of life. Th e last European guidelines for 
the management of HF highlighted the problem of multimorbidity and presented 
a  number of mechanisms by which co-existed diseases can adversely affect HF 
patients [26]. 
Strengths and limitations
Th e strength of the study is the nationwide coverage. Th is is probably the fi rst 
Polish study on the large sample of hospitalized HF patients with analysis data on 
multimorbidity and specifi c co-existed chronic diseases. 
However, the presented study should be interpreted in the context of some limitations. 
First is the potential bias in selection of the patients reported by the physicians. In 
spite of our strong recommendations for the physicians, regarding to the selection of 
the patients to the survey, it cannot be ruled out that selection of the patients might 
have been based on the physicians’ preferences in some cases.
Th e next important limitations are the retrospective study design and lack of 
external verifi cation, both the diagnosis of HF as well as the other collected data. 
Conclusions
Multimorbidity aff ects almost all patients with HF admitted to the hospital. We 
demonstrated diff erent profi le of co-existed chronic diseases according to age and 
gender. Th erefore, the multidisciplinary approach is warranted in particular in elderly 
subjects who suff er from HF.
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